Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 dose-finding study of obeticholic acid in children with biliary atresia after successful Kasai procedure
MOH_2022-09-18_010817Phase 2Not yet recruiting
- Sponsor
- Intercept Pharmaceuticals
- Start
- Sep 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of obeticholic acid in biliary atresia (5 arms), sponsored by Intercept Pharmaceuticals. Primary endpoints: Safety and tolerability of obeticholic acid, Single-dose pharmacokinetics of obeticholic acid and conjugates and 1 more. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
obeticholic acid
03
Conditions
biliary atresia
Beyond the preview
Go deeper on MOH_2022-09-18_010817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-09-18_010817.